The meeting gave investigators across China a common understanding and a firmer basis for standardized multi-center execution, while the expert discussion charted a course for clinical development and international expansion. ImmuneCare looks forward to working with investigators in China to bring this differentiated ActRIIA molecule to patients with pulmonary arterial hypertension as early as possible.

This milestone marks a key progress in the clinical development of IMM0306S in autoimmune diseases and demonstrates the potential to improve long-term treatment experience and adherence for patients.

The application covers the treatment of combined post- and pre-capillary pulmonary hypertension associated with heart failure with preserved ejection fraction ("CpcPH-HFpEF"), a high-risk phenotype within pulmonary hypertension associated with left heart disease ("PH-LHD").

IMC-002 (IMM0306), a bispecific CD20×CD47 fusion protein, demonstrates improvements in active Systemic Lupus Erythematosus patients in a phase Ib/II study

The latest data demonstrate that the combination regimen delivers high response rates, durable progression-free survival benefits, and a favorable safety profile in patients with R/R marginal zone lymphoma (MZL) and R/R follicular lymphoma (FL), offering a highly promising new therapeutic option for patients with R/R indolent B-cell lymphomas. The Phase II clinical study is ongoing.